With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Endeavour Group Ltd (ASX: EDV)
According to a note out of Bell Potter, its analysts have upgraded this drinks giant's shares to a buy rating with a trimmed price target of $4.30. This follows the release of trading update which revealed improving trends during the back end of the first quarter and the start of the second quarter. Looking ahead, Bell Potter believes that recent interest rate cuts and a softer comparable period means that its second quarter performance will be strong and then build positive momentum heading into the April/May strategy refresh. And with expectations in the broker community currently muted, the broker sees potential for a surprise to the upside in FY 2026. As a result, it thinks now could be a good time to snap up this beaten down ASX 200 stock. The Endeavour share price is trading at $3.61 on Monday afternoon.
ResMed Inc. (ASX: RMD)
A note out of Ord Minnett reveals that its analysts have retained their buy rating and $48.80 price target on this sleep treatment disorder company's shares. This follows the release of a first quarter update which impressed the broker. It notes that its mask sales were strong and its focus on cost savings resulted in gross margin improvements ahead of consensus estimates. In response to the update, the broker has increased its earnings per share estimates for FY 2026 and FY 2027 and expects earnings per share growth of 10% for both years. And given its growing cash balance, Ord Minnett highlights that ResMed has capital management optionality. The ResMed share price is fetching $37.85 at the time of writing.
Xero Ltd (ASX: XRO)
Analysts at UBS have retained their buy rating on this cloud accounting platform provider's shares with a trimmed price target of $203.00. According to the note, the broker is expecting a strong half year result from Xero later this month. It is expecting revenue of NZ$1.17 billion, underpinned by the addition of over 200,000 net subscribers and a higher net revenue per user. Looking ahead, UBS expects this strong form to continue, leading to almost 7 million subscribers by FY 2030. This compares to 4.4 million subscribers today. The Xero share price is trading at $146.91.
